The CORRONA Data Collection Program

Trial Profile

The CORRONA Data Collection Program

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Rituximab (Primary) ; Adalimumab; Antirheumatics; Disease-modifying antirheumatics; Tumour necrosis factor inhibitors
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms CERTAIN
  • Most Recent Events

    • 17 Jun 2017 Results evaluating the rate of serious infection events among patients with RA who received only an initial rituximab infusion vs those retreated with more than or equal to 1 rituximab infusion during the first year of therapy, presented at the 18th Annual Congress of the European League Against Rheumatism
    • 17 Jun 2017 Results evaluating a multi-biomarker disease activity score for asessing response to treatment with adalimumab in patients from Corrona CERTAIN study (n=106), presented at the 18th Annual Congress of the European League Against Rheumatism
    • 14 Nov 2016 According to a Bristol Myers Squibb media release, data of two real-world data analyses from ongoing Corrona RA registry will be presented at the 2016 Annual Meeting of the American College of Rheumatology (ACR) and the Association of Rheumatology Health Professionals (ARHP) 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top